Neuroendocrine liver metastases often require multiple modes of treatment to attain disease control, which can utilize various forms of radiolabelled agents either delivered systemically or preferentially towards the liver. A recent trial suggested both safety and efficacy of a novel approach of combining the two to provide a radiation ‘boost’ to hepatic deposits.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Frilling, A. et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 15, e8–21 (2014).
Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335–1342 (2017).
Chen, J. X. et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc. Intervent. Radiol. 40, 69–80 (2017).
Kratochwil, C. et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr. Relat. Cancer 18, 595–602 (2011).
Kennedy, A. et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB 17, 29–37 (2015).
Frilling, A. et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB 21, 773–783 (2019).
Braat, A. J. A. T. et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 21, 561–570 (2020).
Strosberg, J. et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).
Pavel, M. et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103, 172–185 (2016).
Kennedy, A. et al. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: Expert consensus. J. Gastrointest. Oncol. 8, 1079–1099 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.F. reports receiving speaker honoraria from SIRTEX. A.K.C. declares no competing interests.
Rights and permissions
About this article
Cite this article
Frilling, A., Clift, A.K. Combining radiolabelled therapies for neuroendocrine neoplasms. Nat Rev Endocrinol 16, 347–348 (2020). https://doi.org/10.1038/s41574-020-0367-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-020-0367-3
This article is cited by
-
Liver-Directed Therapies for Neuroendocrine Neoplasms
Current Oncology Reports (2021)